Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

van der Graaf, Winette TA; Blay, Jean-Yves; Chawla, Sant P; Kim, Dong-Wan; Bui-Nguyen, Binh; Casali, Paolo G; Schöffski, Patrick; Aglietta, Massimo; Staddon, Arthur P; Beppu, Yasuo; Le Cesne, Axel; Gelderblom, Hans; Judson, Ian R; Araki, Nobuhito; Ouali, Monia; Marreaud, Sandrine; Hodge, Rachel; Dewji, Mohammed R; Coens, Corneel; Demetri, George D; Fletcher, Christopher D; Dei Tos, Angelo Paolo; Hohenberger, Peter; EORTC Soft Tissue and Bone Sarcoma Group,; PALETTE study group,

doi:10.1016/S0140-6736(12)60651-5

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Author:

van der Graaf, Winette TA

Blay, Jean-Yves ; Chawla, Sant P ; Kim, Dong-Wan ; Bui-Nguyen, Binh ; Casali, Paolo G ; Schöffski, Patrick ; Aglietta, Massimo ; Staddon, Arthur P ; Beppu, Yasuo ; Le Cesne, Axel ; Gelderblom, Hans ; Judson, Ian R ; Araki, Nobuhito ; Ouali, Monia ; Marreaud, Sandrine ; Hodge, Rachel ; Dewji, Mohammed R ; Coens, Corneel ; Demetri, George D ; Fletcher, Christopher D ; Dei Tos, Angelo Paolo ; Hohenberger, Peter ; EORTC Soft Tissue and Bone Sarcoma Group, ; PALETTE study group,

Keywords:

Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, EUROPEAN-ORGANIZATION, II TRIAL, ANGIOGENESIS, GEMCITABINE, CARDIOTOXICITY, INHIBITOR, DOCETAXEL, SUNITINIB, IMATINIB, EORTC, Adolescent, Adult, Aged, Antineoplastic Agents, Cross-Over Studies, Disease-Free Survival, Double-Blind Method, Female, Humans, Indazoles, Kaplan-Meier Estimate, Male, Middle Aged, Pyrimidines, Sarcoma, Soft Tissue Neoplasms, Sulfonamides, Treatment Outcome, Young Adult, EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences

Abstract:

Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free survival in patients with metastatic non-adipocytic soft-tissue sarcoma after failure of standard chemotherapy.